Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.94M | 2.44M | 919.00K | 821.80K | 959.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.03M | 2.87M | 2.20M | 998.10K | 2.70M |
| Operating Income | -3.03M | -2.87M | -2.20M | -998.10K | -2.70M |
| Income Before Tax | -3.03M | -2.87M | -2.20M | -1.00M | -2.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.03M | -2.87M | -2.20M | -1.00M | -2.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.03M | -2.87M | -2.20M | -1.00M | -2.70M |
| EBIT | -3.03M | -2.87M | -2.20M | -998.10K | -2.70M |
| EBITDA | -3.00M | -2.84M | -2.17M | -970.40K | -2.67M |
| EPS Basic | -0.68 | -0.72 | -0.58 | -0.30 | -1.28 |
| Normalized Basic EPS | -0.42 | -0.45 | -0.36 | -0.19 | -0.80 |
| EPS Diluted | -0.68 | -0.72 | -0.58 | -0.30 | -1.28 |
| Normalized Diluted EPS | -0.42 | -0.45 | -0.36 | -0.19 | -0.80 |
| Average Basic Shares Outstanding | 4.48M | 3.98M | 3.80M | 3.38M | 2.11M |
| Average Diluted Shares Outstanding | 4.48M | 3.98M | 3.80M | 3.38M | 2.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |